and and very turned Thank afternoon, what a everyone. an XXXX year be out you, good Fiscal dynamic was challenging outstanding for Varex to environment. Chris, despite
we in systems. mind, of As and the healthcare pent many expanding of has an demand for their capabilities uncertainty the diagnostic countries world imaging demand entered COVID effects the year, on were ongoing delivery up the top increase around focus increased by around
levels we the both that output and execute margin, improving said, future year drive reducing and gross progressed, operating demand to to was chain constraints our As our met That our and profitability. challenged on introducing continue growth new profitability. technologies inventory, supply and this products with increased and initiatives, expenses strategic
specialty globally excited demand earnings quarter, quarter, the by million strength record driven working strong revenues and $XXX the was Turning segment, was quarterly to to the fourth capital of finish report the strong year. our cash growth for million $XX strong Profitability in tubes fourth operating to I'm a Broad-based expenses. the in quarter. million. the of Global the in medical Improved stable cash improved CT the in drove industrial and in and medical for year Cash detectors balance from management as drive robust end operations remained applications. the at quarter both helped $XXX flow the generation. demand in and quarter
modalities better pre-COVID above to quarter to pleased say I'm fourth return a for marked quarter many all that the modalities, third the levels saw While or pre-COVID medical levels.
X% were increased guidance in sequentially offset strong of end quarter segments volumes in both revenues revenues quarter and as by margin gross showing the Non-GAAP year-over-year range. of and margins XX% and top fourth exceeded with EPS partially Non-GAAP $X.XX non-GAAP strong were the XX% XX% of Our industrial supply growth. medical the challenges. was operating chain our
Let level into year-over-year. and during me sequentially how modalities revenues quarter. applications our give different you trended and high some XX% the X% segment Medical insight increased
and our [Technical year-over-year. oncology, fourth the We tubes industrial other radiographic, to difficulty] posted modalities, dental due sequential continue in pre-COVID to sequentially CT Fluoro and X% increased the quarter levels. was segment medical timing In XX% and shipments. Revenues flat our growth see in globally were quarter. above mammography, in for of
detectors the gas. soft, for and screening inspection Demand security strong industrial remain more a but demand and borders, well for products for as verticals, screening positive be in ports to our direction. of several During at in battery baggage at digital and imaging as both oil remained quarter airports, for inspection nondestructive continued headed including
to This will other with doing I few are and be detectors we one display software our like make the At nanotubes, on highlight strategic our along at to that past, visible AI-aided products, as such Z invisible is weeks Platform software a our would new LUMEN is photon As counting our outstanding we mission. and the RSNA in detectors. detectors, businesses. have to done in mission Varex, the of in work
year XXXX. business over $XX represented in in software fiscal Our revenue million
of more imaging on we decade leverages efficient a workflow As based globally. software are image more excited AI-aided software that experience represents. diagnostic critical, globally software growth accessible Varex’s becomes of field detection workstations is for more computerated and than about analysis potential and becomes with installed AI-aided thousands are the that
We software connectivity other liver focus continue for it develop the and software to be the we and apply offer to for developing imaging, competencies other clouds. imaging across are have expect neuro via able happy to AI-aided an With we various lung, to and increasing these integration, to breast, modalities. been able on
lung a globally, trusted the think we software platform diagnostic high increased With the has contributor become as Veolity aided software, significant a throughput new industry potential focus Our lung standards screen AI to our Veolity, environments. setting growth. is called for to screening on in an
a we to British screening in and tenders won We for and have Columbia of lung been hospitals tender participating Province Canada. nine the in recently provide globally software
the We other year. the to Europe won adoption United related where a is projects XX,XXX cancer, deaths to The mortality the to cases it's at the and US of lung Veolity and each point broader XX% often in win help disease In there overtime. over lung of treat expect too to drive cancer over and Kingdom cancer XXX,XXX from lung this of rate alone, are about mainly catching high late diagnosis effectively.
and this eligible recommendations have years, lung early global more cancer other to screening. productivity we US, However, CT will encouraged the high-risk among screening X potentially of grow. to Veolity. from to using In of low cancer high could screening and screening number about a software regions the over This few key like enhancing national require for lung capability is following Europe, persons million this continue This nearly the that Canada expect expansion suit, of million. volume increase dose a XX With strength and Asia expansion effective last supports groups.
a diagnostic screening productivity progress Veolity and CT capabilities them offers Our quickly early volume measurement added automated confidence. radiologists perform with over enabling with oversight This can aided enhance tumor for comparisons that of by detection software tracks and of software and help workflow lung the historical time AI with AI can cancer. XD to
and CAGR the XX% last market instances benefit Americas, from to Veolity the at and five million expected we grow a global Varex lung of licenses screening market years, of to XXX Asia. $XX Over from has this growth. expect is across base approximately XXXX, over calendar The Europe in cancer
We innovator about in that and bring can this software is an excited the the aided imaging space. AI are world Varex possibility that proud to
capabilities Varex As become larger applications, software our we business expect we into the this expand AI in to aided a contributor other to future.
minute Sam, to the call reflect like on the I'd to a over hand I to year. past take Before
noted As was Increased levels. drove business fiscal to for across a earlier, new board. our record demand the Varex year XXXX
a EBITDA to strong the XX% an from was impacted translates million. $XXX before strong XXXX, XX% Looking period $XXX was up to in from from to significantly X% to COVID, was while back COVID. the margin, fiscal revenue the million which XXXX, of includes adjusted outstanding still time. increase fiscal by [period] This to effects incremental XXXX of be nearly a up quarter results very a first accomplishment This at
culminated to As million in we XX.X% fiscal fiscal while year revenue, revenue XX% continued led EBITDA while of but were COVID EPS to all fiscal $XX ‘XX position. an million XXXX, the $XXX expense million. exiting from strong fourth actions the growth the to to at recover point the the in $XXX This $X.XX. gross sequential bolster $XXX with strong in over improvement grew adjusted adjusted XXXX. know, took headwinds fourth significant position XXx results and quarterly in of of stronger Robust XXXX drove improved revenue even to us the met margins helped finished from quarter of we our million to in low the financial of This along that management, XXXX quarter demand with record
a we customers very end of global and in I'd all to suppliers XXXX like after environment a record of double and of cash July. down difficult operating period, demand to build In through and even CT being balance meeting fiscal flow upon. $XXX take weather globally our a XXXX, for set cash levels chain for the recognize significant moment to $XX at this $XX digits. generated employees, foundation volumes million elevated continuing million During increased strong our challenges. Fiscal to supply million us our year debt
As XXXX, and ability confident quality customers. supply our products we're deliver demand [Technical our the to we remains Difficulty] move in to into strong,
to focus focus improving COVID the that expanding we around position remain profitability. journey maintaining long continued and on are term. our leadership Varex of innovation chain of expect steadfastly through XXXX, on business The While and we fiscal issues centered our is our focus during supply X.X environment part and
future fiscal several R&D to expenses Our that XXXX expect fully will drive growth. we initiatives include funding
a developing such generation several discussed well. on AI components cardiovascular flexible for radiographic we exciting applications, several software substrate, earlier, as photon detectors test of new products, CT tube and next control As and as detector models advanced counting new have we're for connect CT, and family aided
prototypes have of customer counting CT XXXX. available detector fiscal to of photon second in the quarter modules our expect We
initiatives customers. our innovative innovation increase our for and current and will as expect these other addressable technology We position partner with and market a expand preferred that potential
in are OEMs and local detectors applications, as we While our such China local in innovation surgery. highly cardiovascular, oncology continues in successful be local tubes, platform to now X-ray for with our engaged CT, for on
technologies are we shipping development where making at prototypes a stage progress VEC industrial process Our and our we are nanotube joint to venture is with steady OEMs. in
ongoing improvements and factory, and productivity lower Our supply on profitability designs, cost integration through cost cash by and product driven focus yield investments in vertical our improving are continued actions. generation in and chain reducing
come continue the We uncertainties with way, me to COVID same the In supply hand have expect With a created the and navigate over the weathered globally. to current let and by supply out emerge chain resilient far have uncertainties more we stronger. that, Sam. to so call